Preview

Objective of Financial Statements- a Critical Review

Powerful Essays
Open Document
Open Document
2718 Words
Grammar
Grammar
Plagiarism
Plagiarism
Writing
Writing
Score
Score
Objective of Financial Statements- a Critical Review
The management of all listed companies registered in UK are bound by law to prepare and provide financial statements for each accounting period. This has been the case since the conception of ‘The Companies Act 1948' (Flint, 1982), last amended in 1985. Although it's been over 55 years of reporting entities preparing financial statements, the objective of these statements has always been a matter of discussion. The Accounting Standards Board (ASB) came up with a precise outline in 1999 which stated "The objective of financial statements is to provide information about the reporting entity's financial performance and financial position that is useful to a wide range of users for assessing the stewardship of the entity's management and for making economic decisions" (Accounting Standards Board, 1999). Astrazeneca International is one of the companies which prepare financial statements in compliance with ‘The Companies Act 1985'.This essay is an attempt to critically evaluate the financial information provided by Astrazenca to find out if it meets the objectives set by the above statement. In order to achieve that, it's imperative to first understand the meaning of the highlighted components of the statement and have an overview of the company under discussion.

Astrazeneca: An overview

Astrazeneca is a leading pharmaceutical company formed in 1999 through merger of Astra AB of Sweden and Zeneca group PLC of UK (www.astrazeneca.com). The world pharmaceuticals market was valued at $492 billion in 2004 (Astrazeneca annual report, 2004). Moreover with Astrazeneca pumping in almost $3.8 billion into research and development for new drugs in 2004 at the rate of $15 million per working day makes it an interesting and an ideal entity to analyse (Astrazeneca annual report, 2004).

In addition to the above facts, Astrazeneca being a pioneer in its field will definitely be an ideal entity to study and analyze. Companies in the big league are expected to adhere to the highest



References:  Accounting Standards Board, 1999. Statement of principles for financial reporting, London: ASB.  Flint, D. 1982. A true and fair view. Great Britain. Gee & Co (publishers) limited.  Study Group, 1973.Objectives of financial statements. Newyork. American institute of certified accountants.  Jameson, M. 1988.A practical guide to creative accounting. Guildford. Biddles limited.  Griffiths, I. 1995.New creative accounting. London. Macmillian.  Atril, P and Maclaney, E.2002.3dr Ed. Financial accounting for Non-specialists. Harlow. Pearson Education limited.  Anon,2005.www.astrazeneca.com.(online).accessed on 12 November  Anon, 2001 Statement of accounting concept. Accounting standard review board.  Anon, 2005. Annual report and form 20F information. Astrazeneca.

You May Also Find These Documents Helpful

  • Good Essays

    Perhaps there is no other poet with the influence and storytelling ability as that of Shel Silverstein. Throughout Shel Silverstein's life, he acquired an array of different talents ranging from cartooning to poetry. His most popular works include his book The Giving Tree and the song he composed for popular artist Johnny Cash, "A Boy Named Sue". The remarkableness of his poetry is only equaled by his actual life.…

    • 856 Words
    • 4 Pages
    Good Essays
  • Good Essays

    AstraZeneca is constantly trying to develop new medicines. These medicines must be tested and researched before being put on the market for human use. National and international laws dictate how to record information and data collected and this is one of the goals set forth by AstraZeneca. In order to be in compliance AstraZeneca must follow guidelines for recording data and they must maintain transparency when reporting the collected information. Failure to do so results in fines, loss of funding and grants, and possibly being shut down.…

    • 938 Words
    • 4 Pages
    Good Essays
  • Satisfactory Essays

    When assessing audit risk, should auditors consider the type and number of third parties that may ultimately rely on the client’s financial statements? Should auditors insist that audit engagement letters identify the third parties to whom the client intends to distribute the audited financial statements? Would this practice eliminate auditors’ legal liability to nonprivity parties not mentioned in engagement letters?…

    • 314 Words
    • 2 Pages
    Satisfactory Essays
  • Good Essays

    Financial statements play a significant role in each and every type of business. The financial statements provide a wealth of information to auditors, creditors, investors, suppliers and other important venues that need access to this type of information. This paper will discuss four different types of financial statements and how they are utilized by vendors, creditors and others. The four financial statements that will be reviewed are the income statement, balance sheet, cash flow statements and statement of retained earnings.…

    • 688 Words
    • 3 Pages
    Good Essays
  • Good Essays

    The Pharmaceutical industry has several high entry barriers as shown in figure 1. Economies of scale, product differentiation, government policy and capital requirements and financial services are few barriers for new entrant. Level of threat from rivalry is also high in this industry. Industry has presence of large number of small firms of a similar size. They are in direct competition with one another,…

    • 1056 Words
    • 5 Pages
    Good Essays
  • Best Essays

    Rogers' Chocolates in 2007

    • 4152 Words
    • 17 Pages

    Jones, Paul, and Nic Holladay. "Getting the mix right, Part 1: roadblocks and routes to market; In the first of two articles, Paul Jones and Nic Holladay examine the context in which pharma is currently operating: how new market conditions are emerging; how the industry is responding; and why many companies have been slow to exploit the internet." Pharmaceutical Technology Europe 18.9 (2006): 51+. General OneFile. Web. 19 Oct. 2010.…

    • 4152 Words
    • 17 Pages
    Best Essays
  • Satisfactory Essays

    Financial Statements

    • 1690 Words
    • 7 Pages

    InstructionsIdentify the effect, if any, that each of the following transactions would have upon cash and net income. The first transaction has been completed as an example.…

    • 1690 Words
    • 7 Pages
    Satisfactory Essays
  • Better Essays

    Pharmanet-i3, a subsidiary of inVentive Health, is a world leading clinical research organization committed to the advancement of health around the world. The mission of Pharmanet-i3 is to be a strategic partner to companies that develop therapeutic drugs, and aim to bring drugs to the public that treat disease and improve the quality of life. The company will operate within the industry’s highest quality standards with uncompromising integrity, ethics, and respect for employees, study participants, the environment, and the communities in which the employees live and work. Shareholders can expect superior returns through the implementation of a successful growth strategy (Pharmanet-I3, n.d.).…

    • 1342 Words
    • 6 Pages
    Better Essays
  • Good Essays

    AstraZeneca is a large pharmaceutical company that has a global reach. They are a provider of medications and medical equipment to the Veterans Administration hospitals throughout the United States under federal contract. In 2010, the Department of Labor filed a lawsuit against AstraZeneca on behalf of 124 women who claimed that they were subjected to pay discrimination. AstraZeneca has settled this suit in the amount of $250,000 paid to the complainants.…

    • 536 Words
    • 3 Pages
    Good Essays
  • Best Essays

    References: AstraZeneca’s main six therapy areas represent a significant proportion of the worldwide burden of disease as projections indicate the burden of disease (chronic disease) will continue to increase next 20 years.…

    • 3585 Words
    • 15 Pages
    Best Essays
  • Good Essays

    sugammadox

    • 327 Words
    • 1 Page

    Today’s finance is challenging in the medical environment. Cost seems to be of central concern to decision makers. This could lead you to wonder if research and development can flourish. To develop a new medication is costly and the payoff might appear in jeopardy to those that invest. Recently a new ground breaking drug called Sugammadex has been approved for use in over 40 countries around the world but further delayed in the U.S.…

    • 327 Words
    • 1 Page
    Good Essays
  • Good Essays

    Vigilance Case Study

    • 3498 Words
    • 11 Pages

    An overview about the case, PharMed International, one of the world’s largest pharmaceutical companies established when two formidable pharmaceutical companies, ValMed and PharmCo combined. Officially it’s a merger but in practice it better might have been described as an acquisition of ValMed, a Swiss based company with extensive US operations by PharmCo, French based company. PharMed is required to keep detailed records of how its drugs perform. With that, a database system called VIGILANCE was introduced to track and record adverse events associated with the use of its products under development and already in the market.…

    • 3498 Words
    • 11 Pages
    Good Essays
  • Satisfactory Essays

    * Noncash items: an income item (e.g., depreciation) that does not affect its cash flow…

    • 262 Words
    • 2 Pages
    Satisfactory Essays
  • Satisfactory Essays

    Balance sheet: A balance sheet is a financial statement that shows the assets, liabilities and stockholder’s equity.…

    • 501 Words
    • 3 Pages
    Satisfactory Essays
  • Good Essays

    Azn and Merck

    • 584 Words
    • 3 Pages

    The all-cash deal for MedImmune, worth $58 a share, appears to be the largest purchase ever of an American biotechnology company. The $58 a share AstraZeneca will pay represents a 21 percent premium over MedImmune’s closing price on Friday and is 53 percent higher than MedImmune’s closing price the day before it announced that it would put itself on the block. For AstraZeneca, based in London, the acquisition would help bolster its product pipeline after some recent setbacks, and would supplement its portfolio with biologic drugs — protein-based therapies that are made in cultures of living cells. There is another motive, too: because biotechnology protein drugs are far more complex than typical pills, which are simple chemicals, they have been largely insulated from the generic competition that can wipe out sales of a blockbuster drug almost overnight. The deal will also move AstraZeneca into vaccines. AstraZeneca said the deal would add to its cash earnings per share, excluding amortization, by 2009 and that it could achieve $500 million a year in cost savings.…

    • 584 Words
    • 3 Pages
    Good Essays